GLP-1 Constipation: What Studies Show About Digestion
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
Constipation is a reported adverse reaction in trials of some GLP-1-based medicines. However, constipation, delayed stomach emptying and gastroparesis are different concepts. A symptom cannot identify its cause by itself, and a trial percentage cannot predict what will happen to an individual. This article explains those distinctions and how to read the evidence.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This commercially interested, AI-assisted article is not an independent scientific review.
The evidence below concerns approved medicines and monitored studies. It does not establish the clinical safety of research materials. We reviewed relevant official label sections and original study abstracts, rather than conducting a systematic review or reviewing every full research paper.

Three terms that should not be used interchangeably
Term | What it describes | What it cannot establish alone |
|---|---|---|
Constipation | Difficult passage, hard stools, infrequent stools or incomplete emptying | Whether the stomach empties slowly, or which condition caused the symptom |
Delayed gastric emptying | Food or a test meal leaving the stomach more slowly | A diagnosis based solely on symptoms, or the speed of transit through the entire bowel |
Gastroparesis | A disorder involving delayed stomach emptying without a mechanical blockage | A conclusion that follows automatically from constipation or early fullness |
NIH resources explain constipation symptoms and causes, gastroparesis, and diagnostic testing. A clinical assessment may need to exclude other explanations and directly assess stomach emptying. These distinctions matter because studies measuring one outcome cannot automatically answer questions about the others.
What experiments show about stomach emptying
An early tirzepatide study assessed gastric emptying using acetaminophen absorption, an indirect marker, in participants with and without type 2 diabetes. Emptying was delayed after initial exposure. The effect diminished after repeated exposure in healthy participants, while some delay remained in participants with diabetes undergoing treatment escalation. Original study abstract
That is evidence about a measured physiological effect under particular study conditions. It does not show that everyone develops constipation, establish a gastroparesis diagnosis, or measure every part of intestinal transit. Results also should not be assumed identical across different medicines, formulations and populations.
How often did trials report constipation?
The table uses specific adult trial pools from the US prescribing information reviewed below. Each percentage represents participants reporting the listed adverse reaction, rather than the proportion of bowel movements affected.
Label dataset | Participants and follow-up | Constipation with active treatment | Placebo |
|---|---|---|---|
Wegovy injection: original three-trial adult weight-reduction pool, Table 3 | 2,116 active; 1,261 placebo; treatment up to 68 weeks | 24% | 11% |
Zepbound: two-trial adult weight-reduction pool, Table 1 | Active groups of 630, 948 and 941; 958 placebo; treatment up to 72 weeks | 11%–17% across groups | 5% |
Sources: FDA-hosted Wegovy prescribing information, revised June 2026 and Zepbound US prescribing information, revised November 2026. The two label sections were rechecked November 20, 2026; the FDA-hosted Wegovy label is a dated revision, not a claim that no newer label exists.
The Zepbound range is neither a pooled percentage nor a confidence interval; its label category includes hard stools. Its pooled studies included participants with and without type 2 diabetes. The Wegovy row describes its original injection trial pool, not every formulation or strength now covered by that label.
These are not head-to-head results. Different eligibility criteria, background conditions and reporting methods prevent using this table to declare one medicine safer than another. Neither row provides a retatrutide constipation estimate.
Do digestive symptoms explain the weight-loss effect?
A separate pooled analysis of the STEP semaglutide trials examined gastrointestinal adverse events and weight change. Most recorded digestive events were non-serious and mild to moderate, and occurred most frequently during or shortly after escalation. Its statistical mediation analysis attributed less than one percentage point of the additional weight loss to gastrointestinal events. Original tolerability analysis
That finding argues against treating digestive discomfort as evidence that treatment is “working better.” It also does not mean persistent constipation is unimportant. Event frequency, duration, severity and interference with daily activities are different outcomes; a reassuring average can conceal a difficult individual experience.
Serious reports require careful interpretation
Both labels advise against use with severe gastroparesis and list postmarketing ileus, intestinal obstruction and severe constipation. Such voluntary reports cannot establish incidence or causation. Wegovy label; Zepbound label
NIH advises prompt medical attention when constipation occurs with constant abdominal pain, inability to pass gas, vomiting, fever, rectal bleeding or blood in the stool. Those combinations should not be dismissed as routine treatment effects. NIH warning signs
This is an evidence overview, not a medication adjustment or constipation-treatment protocol. Persistent symptoms require assessment of the person, their medicines and other possible causes.
What better research should report
Useful future studies would distinguish stool consistency, frequency, straining and incomplete emptying rather than relying on a single “constipation” checkbox. They should report onset, duration, recurrence, treatment discontinuation and functional impact. Baseline bowel habits and other medicines matter when interpreting changes.
Studies investigating the mechanism should separately measure stomach emptying and relevant intestinal outcomes. Pairing those measurements with symptom diaries would help test whether a measured delay actually tracks the symptom people experience. These are proposed research priorities, not findings established by the studies above.
Frequently asked questions
Does constipation mean I have gastroparesis?
No. Constipation alone does not establish that diagnosis. Gastroparesis evaluation considers symptoms, other causes and appropriate tests of stomach emptying.
Can trial percentages tell me which medicine will cause fewer symptoms?
They describe groups under particular trial conditions. Separate trials cannot reliably predict an individual's response or support a direct safety ranking.
Do these findings apply to retatrutide or a research vial?
Not automatically. Retatrutide needs its own evidence, and trial results do not validate the clinical safety of retail research materials. See our incretin research comparison and research-use-only explanation.
Review method and source access
Reviewed November 14, 2026. We read relevant sections of the full official Wegovy and Zepbound prescribing-information PDFs, NIH patient-information pages, and original PubMed abstracts for the gastric-emptying and STEP tolerability studies. Full manuscripts and supplements were not independently reviewed. Selected digestive findings are presented, not a complete safety inventory. For interpretation basics, see how to read a peptide study.
References
FDA-hosted Wegovy prescribing information, June 2026 revision
Semaglutide gastrointestinal-tolerability analysis, indexed abstract
On November 20, 2026, we rechecked the named FDA-hosted June Wegovy label, the November Zepbound label, the two indexed abstracts and the NIDDK constipation page. The earlier review of other NIDDK pages retains its original date. These are selected sources; complete study manuscripts and participant-level data were not reviewed in this update.
